NXTC net incomeQ2 2026-$14.89M
NXTC net income was -$14.89M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.81M a year earlier. For the full fiscal 2025 it was -$55.84M, compared with -$55.65M in fiscal 2024.
NextCure Inc. (NXTC) financials
For the twelve months ended Jun 30, 2026, NextCure Inc. reported -$42.75M of net income.
- Net income, TTM
- -$42.75M
- Cash
- $15.26M
- Market cap
- $28.7M
FY2019FY2020
FY2018FY2025
FY2018FY2024
NXTC revenue and earnings growth
NXTC EPSQ2 2026-$2.80
NXTC diluted EPS was -$2.80 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$19.65, compared with -$23.88 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $22.38M | $6.35M | - |
| Research and development | $44.92M | $41.49M | $47.93M | $54.20M | $50.19M | $46.55M | $34.22M | $19.79M |
| Selling, general and admin | $12.69M | $15.72M | $19.71M | $21.71M | $20.57M | $17.05M | $9.61M | $3.41M |
| Operating income | -$57.62M | -$59.75M | -$67.64M | -$75.91M | -$70.77M | -$41.23M | -$37.48M | -$23.20M |
| Interest expense | - | - | - | - | - | $183.0K | $209.0K | $25.0K |
| Income tax | $0 | - | - | - | - | - | - | - |
| Net income | -$55.84M | -$55.65M | -$62.72M | -$74.73M | -$69.39M | -$36.60M | -$33.74M | -$22.80M |
| EPS, basic | -$19.65 | -$23.88 | -$27.00 | -$32.28 | -$30.12 | -$15.96 | -$25.80 | -$199.68 |
| EPS, diluted | -$19.65 | -$23.88 | -$27.00 | -$32.28 | -$30.12 | -$15.96 | -$25.80 | -$199.68 |
| Diluted shares | 2.8M | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M | 1.3M | 114,153.833 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $25.98M | $27.73M | $13.08M | $26.63M | $12.34M | $36.28M | $39.13M | $135.63M |
| Current assets | $43.75M | $71.81M | $112.72M | $163.98M | $227.82M | $287.98M | $340.00M | $135.78M |
| Total assets | $50.18M | $80.86M | $128.04M | $184.16M | $242.39M | $306.64M | $356.17M | $147.63M |
| Current liabilities | $10.57M | $9.57M | $6.88M | $9.13M | $6.61M | $10.32M | $15.04M | $10.30M |
| Short-term debt | - | - | - | - | - | $1.67M | $1.67M | $387.0K |
| Long-term debt | - | - | - | - | - | $1.81M | $3.33M | $73.0K |
| Total debt | - | - | - | $0 | $0 | $3.47M | $5.00M | $460.0K |
| Total liabilities | $15.24M | $15.39M | $13.62M | $16.63M | $9.00M | $12.92M | $34.68M | $32.35M |
| Shareholders' equity | $34.94M | $65.47M | $114.42M | $167.53M | $233.39M | $293.72M | $321.48M | -$46.94M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.61M | -$40.80M | -$52.97M | -$53.89M | -$57.28M | -$44.95M | -$35.62M | $7.99M |
| Capital expenditures | - | $474.0K | $820.0K | $2.12M | $2.36M | $7.13M | $3.37M | $3.06M |
| Free cash flow | - | -$41.28M | -$53.79M | -$56.00M | -$59.64M | -$52.09M | -$38.99M | $4.93M |
| Investing cash flow | $25.56M | $55.31M | $39.27M | $67.98M | $36.60M | $43.52M | -$303.92M | -$3.06M |
| Financing cash flow | $22.31M | $144.0K | $154.0K | $200.0K | -$3.27M | -$1.42M | $243.04M | $121.42M |
| Stock-based compensation | $2.99M | $6.33M | $8.19M | $9.51M | $10.29M | $7.91M | $1.89M | $263.0K |
| Depreciation and amortization | $2.20M | $2.90M | $3.70M | $4.10M | $4.30M | $3.40M | $2.69M | $1.68M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | 252.6% | - | - |
| Operating margin | - | - | - | - | - | -184.2% | -590.5% | - |
| Net margin | - | - | - | - | - | -163.6% | -531.5% | - |
| Free cash flow margin | - | - | - | - | - | -232.8% | -614.4% | - |
| Return on equity | -159.8% | -85.0% | -54.8% | -44.6% | -29.7% | -12.5% | -10.5% | - |
| Return on assets | -111.3% | -68.8% | -49.0% | -40.6% | -28.6% | -11.9% | -9.5% | -15.4% |
| Current ratio | 4.14 | 7.50 | 16.38 | 17.97 | 34.48 | 27.89 | 22.60 | 13.19 |
| Debt to equity | - | - | - | 0.00 | 0.00 | 0.01 | 0.02 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $7.42M | $6.83M | $6.80M | $6.14M | $24.09M | $7.90M | $8.90M | $8.77M | $12.42M | $11.40M | $11.83M | $11.01M |
| Selling, general and admin | $2.59M | $3.27M | $2.96M | $2.81M | $3.20M | $3.73M | $3.55M | $3.73M | $4.08M | $4.36M | $3.96M | $4.61M |
| Operating income | -$15.09M | -$10.11M | -$9.76M | -$8.95M | -$27.29M | -$11.62M | -$12.46M | -$12.49M | -$16.49M | -$18.30M | -$15.79M | -$15.62M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 |
| Net income | -$14.89M | -$9.80M | -$9.44M | -$8.62M | -$26.81M | -$10.98M | -$11.60M | -$11.54M | -$15.40M | -$17.11M | -$14.47M | -$14.30M |
| EPS, basic | -$2.80 | -$1.87 | - | -$3.22 | -$11.29 | -$4.70 | -$5.00 | -$4.95 | -$6.61 | -$7.32 | -$6.24 | -$6.12 |
| EPS, diluted | -$2.80 | -$1.87 | - | -$3.22 | -$11.29 | -$4.70 | -$5.00 | -$4.95 | -$6.61 | -$7.32 | -$6.24 | -$6.12 |
| Diluted shares | 5.3M | 5.2M | - | 2.7M | 2.4M | 2.3M | - | 2.3M | 2.3M | 2.3M | - | 2.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.26M | $15.17M | $25.98M | $7.32M | $4.89M | $21.83M | $27.73M | $27.70M | $20.85M | $18.36M | $13.08M | $19.52M |
| Current assets | $22.25M | $31.74M | $43.75M | $32.64M | $40.02M | $58.90M | $71.81M | $78.69M | $90.45M | $102.55M | $112.72M | $122.68M |
| Total assets | $22.62M | $37.98M | $50.18M | $39.61M | $47.69M | $67.14M | $80.86M | $90.34M | $102.59M | $115.16M | $128.04M | $139.94M |
| Current liabilities | $6.41M | $6.89M | $10.57M | $10.99M | $10.78M | $5.74M | $9.57M | $8.67M | $10.83M | $9.58M | $6.88M | $6.55M |
| Total liabilities | $10.47M | $11.26M | $15.24M | $15.97M | $16.04M | $11.28M | $15.39M | $14.75M | $17.15M | $16.11M | $13.62M | $13.49M |
| Shareholders' equity | $12.15M | $26.72M | $34.94M | $23.65M | $29.65M | $55.85M | $65.47M | $75.59M | $85.44M | $99.05M | $114.42M | $126.45M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.71M | -$13.36M | -$7.64M | -$6.27M | -$22.71M | -$12.99M | -$6.97M | -$11.45M | -$9.78M | -$12.61M | -$10.67M | -$12.78M |
| Capital expenditures | - | - | - | - | - | - | -$34.0K | $170.0K | $301.0K | $37.0K | $13.0K | $279.0K |
| Free cash flow | - | - | - | - | - | - | -$7.00M | -$11.62M | -$10.08M | -$12.64M | -$10.68M | -$13.06M |
| Investing cash flow | $9.79M | $1.30M | $6.00M | $8.70M | $3.76M | $7.09M | $6.96M | $18.31M | $12.16M | $17.88M | $4.16M | $10.28M |
| Financing cash flow | $22.0K | $1.25M | $20.29M | $0 | - | - | $37.0K | $0 | $106.0K | $1.0K | $71.0K | $0 |
| Stock-based compensation | $304.0K | $344.0K | $435.0K | $600.0K | $588.0K | $1.36M | $1.52M | $1.53M | $1.59M | $1.69M | $1.98M | $2.00M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.47 | 4.61 | 4.14 | 2.97 | 3.71 | 10.26 | 7.50 | 9.07 | 8.35 | 10.70 | 16.38 | 18.72 |
Source: XBRL data NextCure Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Aug 7, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NXTC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NXTC | - | - | -$42.75M | - | $28.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
NXTC FAQ
4 questionsIs NXTC profitable?
No. NextCure Inc. reported a net loss of $42.75M for the twelve months ended Jun 30, 2026.How much cash and debt does NXTC have?
NextCure Inc. reported $15.26M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did NXTC last report financial results?
The latest statements here come from NextCure Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this NXTC financial data come from?
Quantisnow builds these statements from the structured XBRL data NextCure Inc. files with the SEC. It is provided for information only and is not investment advice.